Published in Anticancer Agents Med Chem on May 01, 2010
Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) (2011) 2.31
Titanocene-phosphine derivatives as precursors to cytotoxic heterometallic TiAu2 and TiM (M = Pd, Pt) compounds. Studies of their interactions with DNA. Inorg Chem (2011) 0.98
Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents. Organometallics (2012) 0.87
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett (2012) 0.86
In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds. Clin Pharmacol (2010) 0.82
Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity. J Med Chem (2012) 0.82
Identifying therapeutic targets in gastric cancer: the current status and future direction. Acta Biochim Biophys Sin (Shanghai) (2015) 0.81
Different apoptotic effects of [Pt(O,O'-acac)(γ-acac)(DMS)] and cisplatin on normal and cancerous human epithelial breast cells in primary culture. Br J Pharmacol (2014) 0.81
Organic Anion Transporting Polypeptide 5A1 (OATP5A1) in Small Cell Lung Cancer (SCLC) Cells: Possible Involvement in Chemoresistance to Satraplatin. Biomark Cancer (2011) 0.81
Effects of solvents on in vitro potencies of platinum compounds. DNA Repair (Amst) (2011) 0.81
Liposomal delivery and polyethylene glycol-liposomal oxaliplatin for the treatment of colorectal cancer (Review). Biomed Rep (2014) 0.81
Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro. Cancers (Basel) (2011) 0.81
Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin. Cancers (Basel) (2014) 0.78
Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells. Pharm Res (2013) 0.78
Heterometallic titanium-gold complexes inhibit renal cancer cells in vitro and in vivo. Chem Sci (2015) 0.78
Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells. J Exp Pharmacol (2011) 0.76
Platinum-Based Drugs and DNA Interactions Studied by Single-Molecule and Bulk Measurements. Biophys J (2016) 0.75
Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies. Biomolecules (2017) 0.75
Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer. Int J Nanomedicine (2017) 0.75
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest (2003) 1.21
Synthesis of compounds with antiproliferative activity as analogues of prenylated natural products existing in Brazilian propolis. Eur J Med Chem (2006) 0.96
Anticancer drug cis-4-hydroxy-L-proline: Correlation of preclinical toxicology with clinical parameters of liver function. Mol Med Rep (2011) 0.95
Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg (2009) 0.91
In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol (2011) 0.90
Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver Int (2006) 0.89
Mechanisms of cytotoxicity of anticancer titanocenes. Anticancer Agents Med Chem (2010) 0.87
Alterations of phosphoproteins in NCI-H526 small cell lung cancer cells involved in cytotoxicity of cisplatin and titanocene Y. Neoplasia (2012) 0.85
Activation of Na+/H+ exchanger 1 by neurotensin signaling in pancreatic cancer cell lines. Biochem Biophys Res Commun (2010) 0.85
Neurotensin signaling induces intracellular alkalinization and interleukin-8 expression in human pancreatic cancer cells. Mol Oncol (2009) 0.85
The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors. J Drug Deliv (2013) 0.82
Anticancer activity and mode of action of titanocene C. Invest New Drugs (2010) 0.82
In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds. Clin Pharmacol (2010) 0.82
In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent. Met Based Drugs (2009) 0.81
Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro. Cancers (Basel) (2011) 0.81
Dependence of Relative Expression of NTR1 and EGFR on Cell Density and Extracellular pH in Human Pancreatic Cancer Cell Lines. Cancers (Basel) (2011) 0.78
Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy. Open Access J Urol (2010) 0.77
Effects of 1alpha,25-dihydroxy-vitamin D3 pretreatment and MAP kinase inhibitor PD 98059 on response of osteoblasts to prostate-derived osteoblastic factors. Oncol Rep (2003) 0.77
Circulating cytokeratin 18 fragments and activation of dormant tumor cells in bone marrow of cancer patients. Exp Ther Med (2010) 0.76
Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. Anticancer Drugs (2009) 0.76
Steroid hormone metabolizing enzymes in benign and malignant human bone tumors. Expert Opin Drug Metab Toxicol (2010) 0.76
Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results. Melanoma Res (2005) 0.75
Effects of two disiloxanes ALIS-409 and ALIS-421 on chemoprevention in model experiments. Anticancer Res (2013) 0.75
Anticancer effects of the organosilicon multidrug resistance modulator SILA 421. Anticancer Agents Med Chem (2012) 0.75